TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04625465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Text Messaging
Description: Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order, with content equally distributed across the four content areas (i.e., psychoeducation regarding effects of stress, distress tolerance, emotion regulation, alcohol reduction).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Text Messaging
Description: Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order, with content equally distributed across the four content areas (i.e., psychoeducation regarding effects of stress, distress tolerance, emotion regulation, alcohol reduction).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Text Messaging
Description: Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order, with content equally distributed across the four content areas (i.e., psychoeducation regarding effects of stress, distress tolerance, emotion regulation, alcohol reduction).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Text Messaging
Description: Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order, with content equally distributed across the four content areas (i.e., psychoeducation regarding effects of stress, distress tolerance, emotion regulation, alcohol reduction).
Study: NCT03108495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
Study: NCT04625465

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Text Messaging
Description: Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order. All texts will be supportive messages which express empathy and unconditional positive regard and provide support for dealing with stressors. These messages will be nondirective and will not include any CBT skill suggestions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Text Messaging
Description: Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order. All texts will be supportive messages which express empathy and unconditional positive regard and provide support for dealing with stressors. These messages will be nondirective and will not include any CBT skill suggestions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Text Messaging
Description: Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order. All texts will be supportive messages which express empathy and unconditional positive regard and provide support for dealing with stressors. These messages will be nondirective and will not include any CBT skill suggestions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Text Messaging
Description: Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order. All texts will be supportive messages which express empathy and unconditional positive regard and provide support for dealing with stressors. These messages will be nondirective and will not include any CBT skill suggestions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Text Messaging
Description: Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order. All texts will be supportive messages which express empathy and unconditional positive regard and provide support for dealing with stressors. These messages will be nondirective and will not include any CBT skill suggestions.
Study: NCT03425578

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MSG
Description: 150 mg/kg body mass monosodium glutamate (MSG).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MSG
Description: 150 mg/kg body mass monosodium glutamate (MSG).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CHO
Description: 75g CHO (i.e. dextrose)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CHO
Description: 75g CHO (i.e. dextrose)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo A
Description: A non-caloric placebo composed of table salt (NaCl) and sucralose (Splenda).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo B
Description: A non-caloric placebo composed of flavoured water.
Study: NCT04604444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Intensive Rehabilitation of Aphasia and Apraxia of Speech
Description: Intensive Comprehensive Aphasia (ICAP) and Apraxia of Speech Program
Study: NCT03858725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D569 Tab.
Description: D569 Tab. 1T single oral administration under fasting condition
Study: NCT03268850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: All patients participating in the study will continue to receive usual care. Kidney transplant (KT) candidates are advised that live donor kidney transplantation (LDKT) is their best treatment option and are encouraged to initiate living donor (LD) discussions with family members and friends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: All patients participating in the study will continue to receive usual care. Kidney transplant (KT) candidates are advised that live donor kidney transplantation (LDKT) is their best treatment option and are encouraged to initiate living donor (LD) discussions with family members and friends.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wage Reimbursement A
Description: Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount, based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wage Reimbursement B
Description: Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount (different from LW-A), based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria.
Study: NCT04299971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate Tablets
Description: The methotrexate group is prescribed with methotrexate Tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of methotrexate is maintained for another 24 weeks, otherwise (resistant), patients would be given tofacitinib (5.0mg.bid.p.o.) for 24 weeks instead.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib tablet
Description: The tofacitinib group is prescribed with tofacitinib tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of tofacitinib is maintained for another 24 weeks, otherwise (resistant), patients would be given methotrexate (15.0mg.qw.p.o.) for 24 weeks instead.
Study: NCT03742232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG3350
Description: PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.~PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrogol 4000
Description: SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.~SELG-ESSE® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
Study: NCT01372202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.
Study: NCT03108495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145 + pembrolizumab
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. The first dose of anti-PD-1 immunotherapy will be administered following tumor resection.
Study: NCT06611683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: A threshold inspiratory muscule device used a starting resistance set at 30% maximum inspiratory pressure, connecting to subject artificial airway. The subjects were then instructed to perform fast and forceful inspirations against added inspiratory resistance. The inspiratory muscle training was conducted twice daily over five consecutive days, followed by a two-day rest period. This regimen continued for three consecutive weeks or until the subject no longer required ventilator support.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Routine care
Description: Subjects received routine care without intervention.
Study: NCT03417037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Administered orally daily, 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Administered orally daily, 100 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Platinum-based doublet chemotherapy
Study: NCT01372202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Paclitaxel and cisplatin:~* Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.~* Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1- 4 and 29 - 32.~* Cisplatin 75 mg/m² days 1, 29.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Paclitaxel and cisplatin:~* Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.~* Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1- 4 and 29 - 32.~* Cisplatin 75 mg/m² days 1, 29.
Study: NCT03858725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D569 Tab.
Description: D569 Tab. 1T single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-374 5mg Tab.
Description: CKD-374(Tofacitinib) 5mg Tab. 1T single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-374 5mg Tab.
Description: CKD-374(Tofacitinib) 5mg Tab. 1T single oral administration under fasting condition
Study: NCT01089764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couplelinks.ca website
Description: Participation in the Couplelinks.ca program, an online intervention.
Study: NCT03917316

Intervention type: OTHER
Intervention: Language and neuropsychological tests
Description: Tests related to language, narrative and specific and general cognitive function
Study: NCT03417037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Platinum-based doublet chemotherapy
Study: NCT01372202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Paclitaxel and cisplatin:~* Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.~* Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1- 4 and 29 - 32.~* Cisplatin 75 mg/m² days 1, 29.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2 days 1, 15, 29.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Oxaliplatin and 5-fluorouracil:~* Oxaliplatin 85 mg/m2 days 1, 15, 29.~* 5-Fluorouracil 180 mg/m2 prolonged infusion starting day 1 of radiation and completing on the final day of radiation (up to 40 days)~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1-4 and 29-32.~* Cisplatin 75 mg/m² days 1, 29.
Study: NCT00608725

Intervention type: RADIATION
Group type: OTHER
Intervention: DAXOR
Description: 131-I-Human Serum Albumin Blood Volume Assessment Kit

Intervention type: RADIATION
Group type: OTHER
Intervention: DAXOR
Description: 131-I-Human Serum Albumin Blood Volume Assessment Kit

Intervention type: PROCEDURE
Group type: OTHER
Intervention: QSweat
Description: Quantitative Sweat Testing

Intervention type: PROCEDURE
Group type: OTHER
Intervention: QSweat
Description: Quantitative Sweat Testing

Intervention type: DRUG
Group type: OTHER
Intervention: Intrinsic Heart Rate
Description: Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses

Intervention type: DRUG
Group type: OTHER
Intervention: Intrinsic Heart Rate
Description: Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
Study: NCT04222062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine 7.7Mg Wafer
Description: GLIADEL wafers will be placed to cover tumor bed immediately after tumor removal.
Study: NCT06625164

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: core stabilization exercises
Study: NCT04159519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort®
Description: Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation or Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort®
Description: Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation or Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasenra®
Description: Participants will receive Benralizumab 30 mg/mL, 1 mL fill volume via subcutaneous injection every 4 weeks for first 3 doses (prior to study inclusion), every 8 weeks thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasenra®
Description: Participants will receive Benralizumab 30 mg/mL, 1 mL fill volume via subcutaneous injection every 4 weeks for first 3 doses (prior to study inclusion), every 8 weeks thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ventolin®
Description: Participants will receive Salbutamol sulfate 100 μg per inhalation as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ventolin®
Description: Participants will receive Salbutamol sulfate 100 μg per inhalation as needed.
Study: NCT00441376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox
Description: 15 ml vial containing 2mg/ml Doxorubicin HCl, DPPC, MSPC, DSPE-MPEG 2000. Administered as single dose intravenously over 30 minutes. Dose is determined by dose cohort patient enters study.
Study: NCT05002673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DENTAL LOCAL ANESTHESİA
Description: doing local and topical anesthesia with two different device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DENTAL LOCAL ANESTHESİA
Description: doing local and topical anesthesia with two different device
Study: NCT03604679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB C-0501
Description: Specified dose on specified days
Study: NCT02775149

Intervention type: OTHER
Intervention: Collection of saliva samples
Description: Collection of saliva samples

Intervention type: OTHER
Intervention: Visual detection of BEWE-index
Description: Visual detection of BEWE-index
Study: NCT02222311

Intervention type: OTHER
Intervention: Blood Samples

Intervention type: OTHER
Intervention: Blood Samples

Intervention type: OTHER
Intervention: Blood Samples
Study: NCT03031249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid
Description: ATRA at a dose of 30mg/㎡/d on day 1-14.
Study: NCT01372202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Oxaliplatin and 5-fluorouracil:~* Oxaliplatin 85 mg/m2 days 1, 15, 29.~* 5-Fluorouracil 180 mg/m2 prolonged infusion starting day 1 of radiation and completing on the final day of radiation (up to 40 days)~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1-4 and 29-32.~* Cisplatin 75 mg/m² days 1, 29.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Patients will be treated 5 days/week at 1.8 Gy/day to a total dose of 45Gy.
Study: NCT03031249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: ATO at a dose of 10mg/d on day 1-14
Study: NCT01372202

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Patients will be treated 5 days/week at 1.8 Gy/day to a total dose of 45Gy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Patients will be treated 5 days/week at 1.8 Gy/day to a total dose of 45Gy.
Study: NCT00576160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PST therapy
Description: Problem-Solving Therapy (PST) is a behavioral approach that teaches patients how to systematically solve their own behavioral difficulties. During telephone treatment sessions, the patient will discuss the problems and difficulties they face and that give rise to medication non-adherence.
Study: NCT02901743

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root planing
Description: All the patients were asked to use a preprocedural mouthrinse and scaling and rootplaning was done using ultrasonic scalers.
Study: NCT02924389

Intervention type: DRUG
Group type: OTHER
Intervention: dolutegravir
Description: Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 50 mg of Tivicay (dolutegravir) will be taken orally once a day.
Study: NCT02836379

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02171338

Intervention type: OTHER
Group type: OTHER
Intervention: PCT-level
Description: PCT-level is available to the treating doctor.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Antibiotic treatment based on PCT-level
Description: PCT-level is available to the treating doctor and the decision whether or not to treat with antibiotic is based on the level of PCT.~The type of antibiotic chosen to treat is based on the existing antibiotic treatment guidelines of Holbaek Hospital and includes the antibiotics listed above.
Study: NCT01542723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMWH
Description: Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily).
Study: NCT01369030

Intervention type: OTHER
Intervention: Deplin®
Description: Deplin® is an orally administered medical food available in a 7.5mg tablet or a 15mg caplet with each containing either 7.5mg or 15mg of L-methylfolate, respectively - which is the primary biologically active and immediately bioavailable form of folate. Dosage for this study will be 1 15mg caplet QD.
Study: NCT01372202

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: The type of resection (Ivor-Lewis, Transhiatal, etc.) will be left to the discretion of the operating surgeon. Resection will be completed between 5 and 8 weeks starting from the completion of chemotherapy and radiation (days 36 - 56).